Dr. Jonathan Aschoff is a managing director at Opus National Capital Markets. Prior to joining the firm in 2016, he held positions as a senior biotechnology analyst at Brean Murray, Carret & Co. and Friedman Billings Ramsey & Co. Inc., as a senior analyst at what is now RBC Inc. and also served as an analyst at Sturza Institutional Research. Prior to his work on Wall Street, Dr. Aschoff was a research technician at New England Medical Center. It was at Tufts University that Dr. Aschoff earned his Ph.D. in molecular biology and microbiolog,y as well as his bachelor's degree in biology.
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.